NCT04556292View on ClinicalTrials.gov

A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

March 30, 2022

Study Completion Date

August 30, 2022

Conditions
Breast Cancer MetastaticBRCA 1 Gene MutationBRCA 2 Gene Mutation
Interventions
DRUG

SC10914

SC10914 400mg tid

Trial Locations (1)

200000

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
lead

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

INDUSTRY